LKPC(SH:600789) 智通财经网·2025-12-26 09:57Core Viewpoint - The announcement indicates that LuKang Pharmaceutical's subsidiary, Shandong LuKang Pharmaceutical Group Sait Company, has received a drug registration certificate for Finasteride tablets, marking a significant milestone in the company's product portfolio and regulatory compliance [1] Group 1: Product Approval - The drug registration certificate for Finasteride tablets was issued by the National Medical Products Administration, with approval numbers 2025S03900 and 2025S03901 [1] - Finasteride is classified as a Category 4 generic drug, having passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Drug Mechanism and Applications - Finasteride acts as a specific inhibitor of the enzyme 5α-reductase type II, which is involved in the metabolism of testosterone to dihydrotestosterone (DHT) [1] - The 1mg formulation is indicated for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss [1] - The 5mg formulation is used for the treatment and management of benign prostatic hyperplasia (BPH), helping to reduce prostate size and improve urinary flow and symptoms related to prostate enlargement [1]